ロード中...
Differential Sensitivity of Wild-Type and BRAF-Mutated Cells to Combined BRAF and Autophagy Inhibition
BRAF inhibitors are insufficient monotherapies for BRAF-mutated cancer; therefore, we investigated which inhibitory pathway would yield the most effective therapeutic approach when targeted in combination with BRAF inhibition. The oncogenic BRAF inhibitor, PLX4720, increased basal autophagic flux in...
保存先:
| 出版年: | Biomol Ther (Seoul) |
|---|---|
| 主要な著者: | , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
The Korean Society of Applied Pharmacology
2021
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8255135/ https://ncbi.nlm.nih.gov/pubmed/33551379 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4062/biomolther.2020.203 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|